Completed PHASE3 INTERVENTIONAL NCT00056524

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.

Sponsor: Avanir Pharmaceuticals

Conditions Alzheimer's Disease Parkinson's Disease Stroke Traumatic Brain Injury

Interventions AVP-923

Updated 6 times since 2017 Last updated: Jul 13, 2016 Started: Feb 28, 2003 Primary completion: Jun 30, 2007 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alzheimer's Disease and Parkinson's Disease, this trial is completed. The trial is conducted by Avanir Pharmaceuticals and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avanir Pharmaceuticals

Data source: Avanir Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Allentown, United States , Amherst, United States , Bellaire, United States , Burlington, United States , Canton, United States , Charlotte, United States , Cleveland, United States , Darien, United States , Decatur, United States and 24 more locations